In addition, Li et al. found that deletion of ApoC3 from LDLR−/− mice has no impact on lipid metabolism and atherogenesis, indicating that targeting ApoC3 to treat hyperlipidemia and CVD needs to be further validated. Here, APOC3 is linked to hyperlipidemia.